PPIDT00385

Drug Information
NameErenumab
SequenceQVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVISFDGSIKYSVDSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCARDRLNYYDSSGYYHYKYYGMAVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DrugBank_IDDB14039
Typebiotech
IndicationErenumab is indicated for the preventative treatment of migraine in adults [FDA Label].
Dosage Forms
Form Route Strength
Injection Subcutaneous
70 mg/ml
Injection Subcutaneous
70 mg/1mL
Injection, solution Subcutaneous
140 mg/1mL
Injection, solution Subcutaneous
140 MG
Injection, solution Subcutaneous
70 MG
Solution Subcutaneous
140 mg / mL
Solution Subcutaneous
70 mg / mL
Injection, solution Subcutaneous
70 mg/1ml
Injection, solution Subcutaneous
70 mg/ml
Injection, solution Subcutaneous
140 MG/ML
Solution Subcutaneous
70.000 mg
Solution Subcutaneous
140 mg/ml
Solution Subcutaneous
14000000 mg
Solution Subcutaneous
7000000 mg
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
target Q16602 CALCRL Calcitonin gene-related peptide type 1 receptor Homo sapiens antagonist Link